|
|
|
|
HIV-thrombocytopenia therapy infusion fraud: Miami Physician Sentenced to 97 Months in Prison for Role in $10
Miami physician Roberto Rodriguez, 54, was sentenced today to 97 months in prison for his role in a Medicare fraud scheme involving HIV infusion services, announced Assistant Attorney General Lanny A.Breuer of the Criminal Division,...
|
|
|
Cancer drug cure hope in Bundoora
Bundoora resident Dr Kylie Mason has made an important breakthrough in cancer research.GROUND-BREAKING research by a Bundoora scientist may lead to the creation of a drug which could see a major breakthrough in the fight against cancer.
|
|
|
Doctors In Boulder Use Patients' Blood To Heal
'We are fooling the body into healing itself,' said Dr.Roger Nichols, radiologist and chief of staff at Boulder Community Hospital. Platelets are most commonly known for their clotting factor, but in the case of PRP therapy it's...
|
|
|
Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
Peake to provide guidance and direction regarding military needs, clinical uses and funding sources ROCKVILLE, Md., June 30 /PRNewswire/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced today that former...
|
|
|
Clue to Greater Aspirin Resistance in Women vs. Men
Although platelet function varies widely among individuals, mainly due to inherited factors, women tend to have higher platelet reactivity at baseline and are less responsive to aspirin than men, according to a study published...
|
|
|
Platelet Activating Factor/Platelet Activating Factor Receptor Pathway as a Potential Therapeutic Target in Au
Save in Edwards LJ et al.- Recent experiments from the laboratory show that PAF/PAF-R pathway may influence T cell responses and favour the Th17 phenotype. The PAF/PAF-R pathway is a promising target for pharmacological intervention in...
|
|
|
'Stocks that Standout' picks for today are: CYTR, GNBT, MMTC, TEVA
'Stocks that Standout' picks for today are: CytRx Corporation (NASDAQ: CYTR), Generex Biotechnology Corporation (Nasdaq: GNBT), Micro Imaging Technology, Inc.(OTCBB: MMTC), Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA)! Visit Us...
|
|
|
New Treatment For Receding Gums: No Pain, Lots Of Gain
Tufts dental researchers conducted a three-year follow-up study that examined the stability of a treatment option for receding gums and found that complete root coverage the goal of the surgery had been maintained.This specific tissue...
|
|
|
New Treatment for Receding Gums: No Pain, Lots of Gain
Newswise Tufts dental researchers conducted a three-year follow-up study that examined the stability of a treatment option for receding gums and found that complete root coverage the goal of the surgery had been maintained.This specific...
|
|
|
CytRx Reports Favorable Progress Update For Its Pivotal Phase 2 Trial With Tamibarotene As A Third-Line Treatm
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, provided a favorable progress update for its ongoing Phase 2 STAR-1 registration clinical...
|
|
|
Hyaline-like tissue seen in defects treated with stem cells and platelet rich plasma
Analysis showed a higher relation between Collagen I and II after stem cell treatments.ORTHOPEDICS TODAY 2009; 29:28 MIAMI Treating chondral defects with mesenchymal stem cells delivered in a scaffold with platelet-rich plasma may...
|
|
|
[Head and Neck Cancer] Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symp
This Article Google Scholar Social Bookmarking Received June 26, 2008 Accepted February 9, 2009 Martin J.Schlumberger,* Rossella Elisei, Lars Bastholt, Lori J. Wirth, Renato G. Martins, Laura D. Locati, Barbara Jarzab, Furio Pacini,...
|
|
|
Blood drive to honor cancer patient
The Western Lake Erie Blood Services Region of the American Red Cross will sponsor a blood drive in honor of Dugan Smith from noon to 6 p.m.July 11 at the Fostoria High School gym. Dugan, 10, was diagnosed with osteogenic...
|
|
|
Relationship Between Platelet Activation and Acute Rejection After Renal Transplantation
(Click the title below to leave the MDLinx Network and go to the Journal's Website) Transplantation Proceedings, 06/29/09 Print Save in My Library Free Abstract Zhang Y et al.- Our studies demonstrate an association between platelet...
|
|
|
Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
Peake to provide guidance and direction regarding military needs, clinical uses and funding sources ROCKVILLE, Md., June 30 /PRNewswire/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced today that former...
|
|
|
Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
Peake to provide guidance and direction regarding military needs, clinical uses and funding sources ROCKVILLE, Md., June 30 /PRNewswire/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced today that former...
|
|
|
Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors
Peake to provide guidance and direction regarding military needs, clinical uses and funding sources ) ROCKVILLE, Md., June 30, 2009 /PRNewswire via COMTEX/ -- Cellphire, Inc., a biotechnology company located in Rockville, Md., announced...
|
|
|
Hydroxyethyl Starch Interferes with Human Blood Coagulation, Platelet Function and Sedimentation
Report Shows Shift in Starting Salaries for Physicians 2.2008 Exclusive SurveyEarnings: Good news for primary care income 3. Hydroxyethyl Starch Interferes with Human Blood Coagulation, Platelet Function and Sedimentation.<...
|
|
|
CytRx Reports Favorable Progress Update for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as a Third-li
The primary endpoint of the open-label, non-randomized STAR-1 trial is to determine the rate of durable complete response for tamibarotene therapy when administered as a single agent to adult patients following treatment failure with all...
|
|
|
CytRx Reports Favorable Progress Update for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as a Third-li
- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today provided a favorable progress update for its ongoing Phase 2 STAR-1 registration...
|
|
|
CytRx Reports Favorable Progress Update for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as a Third-li
Companies mentioned in this article: CytRx Corporation LOS ANGELES -- (BUSINESSWIRE) -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today...
|
|
|
CytRx Reports Favorable Progress Update for Its Pivotal Phase 2 Clinical Trial with Tamibarotene as a Third-li
News source: Business Wire CytRx Corporation (NASDAQ: CYTR) The primary endpoint of the open-label, non-randomized STAR-1 trial is to determine the rate of durable complete response for tamibarotene therapy when administered as a single...
|
|
|
SVG occlusion not linked to anti-heparin/PF4 antibodies
MedWire News: Antibodies to heparin and platelet factor 4 (PF4) complexes are not independently associated with early saphenous vein graft (SVG) occlusion or adverse clinical outcomes after coronary artery bypass graft (CABG) surgery,...
|
|
|
Shots over Surgery
Suffering from a torn ligament or tendon doesn't always have to mean going under the knife.Now one local doctor is offering a non-invasive treatment that's giving patients pain-relief. Seven's Diana Diaz shows us why some are choosing....
|
|
|
Committee For Medicinal Products For Human Use Summary Of Positive Opinion For Clopidogrel Ratiopharm
International Nonproprietary Name (INN): clopidogrel LONDON, June 25, 2009-On 25 June 2009 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion,** recommending to grant a marketing authorisation for the...
|
